Published Research
Dr. Green's research spans therapeutic plasma exchange, transfusion medicine, apheresis technologies, and hematology — with publications in peer-reviewed journals and presentations at national conferences.
Clinical research is the foundation of evidence-based practice. Dr. Green has contributed to the literature on apheresis optimization, novel treatment approaches in hematology, and diagnostic validation — work that directly informs the protocols used at Global Apheresis today.
Peer-Reviewed Publications
Technological advances in selective plasma adsorption: The MTx.100 column and the emergence of subtractive precision medicine.
Transfusion and Apheresis Science. 2026;65(4):104484.
Reviews the MTx.100 selective adsorption column as a shift beyond non-selective plasma exchange toward subtractive precision medicine, targeting pathogenic cytokines and protein-bound toxins while sparing protective immunoglobulins, coagulation factors, and albumin.
View PaperTherapeutic apheresis in transition: New indications and the emergence of precision apheresis.
Transfusion and Apheresis Science. 2026;65:104480.
Opening editorial for the guest-edited theme issue, framing the field's shift from non-selective plasma exchange toward precision apheresis and introducing the four contributions that map that transition.
View PaperTailoring caplacizumab administration using ADAMTS13 activity for immune-mediated thrombotic thrombocytopenic purpura.
Blood Vessels, Thrombosis & Hemostasis. 2024.
Demonstrates a personalized approach to caplacizumab dosing guided by ADAMTS13 activity monitoring, optimizing treatment duration and outcomes in immune-mediated TTP.
View PaperA case of hyperhemolysis syndrome in sickle cell disease and concomitant COVID-19.
Transfusion and Apheresis Science. 2023.
Reports a novel case highlighting the intersection of hyperhemolysis syndrome in sickle cell disease complicated by concurrent SARS-CoV-2 infection.
View PaperSuccessful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy.
Annals of Hematology. 2022.
First reported use of lenalidomide for refractory acquired von Willebrand disease in the setting of monoclonal gammopathy — a novel therapeutic approach.
View PaperIdentification of potential antiviral compounds against SARS-CoV-2 structural and non-structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset.
Computers in Biology and Medicine. 2021.
Machine-learning and molecular-docking pharmacoinformatics screen of the CAS COVID-19 compound dataset to identify candidate SARS-CoV-2 antivirals.
View PaperClinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups.
Journal of Clinical Microbiology. 2021.
Clinical validation of COVID-19 antibody assays, supporting diagnostic accuracy during the pandemic.
View PaperThe utility of therapeutic plasma exchange in hyperviscosity syndrome associated with juvenile rheumatoid arthritis: A case report.
Journal of Clinical Apheresis. 2021.
Demonstrates the application of TPE for hyperviscosity syndrome in the context of juvenile rheumatoid arthritis — directly relevant to the autoimmune applications of apheresis.
View PaperGuest-Edited Theme Issue
Dr. Green served as co-guest editor of a 2026 theme issue of Transfusion and Apheresis Science, “Therapeutic Apheresis: Novel Indications and Emerging Technologies,” convened with Dr. Dobri Kiprov. The issue maps the field's shift from non-selective plasma exchange toward selective, component-targeted apheresis across neurodegeneration, post-infectious immune dysregulation, cardiovascular and renal disease, and emerging column technology. Dr. Green co-authored the opening editorial and a review of selective adsorption technology.
Therapeutic apheresis in transition: New indications and the emergence of precision apheresis.
View PaperTherapeutic plasma exchange in Alzheimer's disease: From clinical trial to real-world evidence.
View PaperTherapeutic plasma exchange and immunomodulatory strategies in post-infectious syndromes: A review of immune dysregulation in PTLDS, long COVID, ME/CFS, and PANS/PANDAS.
View PaperLipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease.
View PaperTechnological advances in selective plasma adsorption: The MTx.100 column and the emergence of subtractive precision medicine.
View PaperConference Abstracts & Posters
Sodium citrate anticoagulant for apheresis port patency
American Society for Apheresis (ASFA) Annual Conference
Evaluating sodium citrate as an anticoagulant lock solution for maintaining apheresis port patency — addressing a practical clinical challenge in serial TPE patients.
Response to therapeutic plasma exchange in two patients with systemic sclerosis
American Society for Apheresis (ASFA) Annual Meeting, Minneapolis, MN
Co-authored abstract examining TPE outcomes in systemic sclerosis patients — contributing to the evidence base for apheresis in autoimmune fibrotic conditions.
The impact of Rh/K antigen matching for chronic red cell exchanges in sickle cell disease
AABB Annual Meeting
Evaluating the clinical impact of extended antigen matching protocols in chronic transfusion support for sickle cell patients.
Oral Presentations
Continued unfractionated heparin infusion during therapeutic plasma exchange: a retrospective analysis
American Society for Apheresis (ASFA) Annual Conference, Las Vegas
Retrospective analysis evaluating the safety and efficacy of maintaining heparin infusions during TPE procedures, informing anticoagulation management best practices.
Therapeutic Plasma Exchange: A Deep Dive into Mechanisms and Therapeutic Potential
UT Southwestern Medical Center, Department of Pathology — Update in Pathophysiology lecture series
Presentation covering the mechanistic basis of TPE and its expanding therapeutic applications, delivered to the department where Dr. Green completed his residency training.
Research at Global Apheresis
Dr. Green's personal research in apheresis optimization and autoimmune therapeutics complements a broader research environment at Global Apheresis. The facility has been the clinical site for landmark studies in TPE and aging — including the Kim et al. study on plasma dilution and biological age (GeroScience, 2022) and the Fuentealba et al. randomized trial on biological age rejuvenation (Aging Cell, 2025), both conducted in collaboration with Dr. Dobri Kiprov. While these studies are not Dr. Green's publications, the protocols and insights they generated directly inform clinical practice at Global Apheresis.
Have Questions About Our Research?
Dr. Green welcomes inquiries from patients, referring physicians, and research collaborators. Schedule a discovery call to discuss how published research informs the treatment protocols at Global Apheresis.